Hepatobiliary cancers, version 2.2019 featured updates to the NCCN guidelines

Al B. Benson, Michael I. D'Angelica, Daniel E. Abbott, Thomas A. Abrams, Steven R. Alberts, Daniel A. Anaya, Robert Anders, Chandrakanth Are, Daniel Brown, Daniel T. Chang, Jordan Cloyd, Anne M. Covey, William Hawkins, Renuka Iyer, Rojymon Jacob, Andreas Karachristos, R. Kate Kelley, Robin Kim, Manisha Palta, James O. ParkVaibhav Sahai, Tracey Schefter, Jason K. Sicklick, Gagandeep Singh, Davendra Sohal, Stacey Stein, G. Gary Tian, Jean Nicolas Vauthey, Alan P. Venook, Lydia J. Hammond, Susan D. Darlow

Research output: Contribution to journalArticlepeer-review

83 Scopus citations

Abstract

The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel's discussion and updated recommendations regarding systemic therapy for first-line and subsequent-line treatment of patients with hepatocellular carcinoma.

Original languageEnglish (US)
Pages (from-to)302-310
Number of pages9
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume17
Issue number4
DOIs
StatePublished - Apr 2019

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Hepatobiliary cancers, version 2.2019 featured updates to the NCCN guidelines'. Together they form a unique fingerprint.

Cite this